Alamar Biosciences IPO
Alamar Biosciences develops ultrasensitive protein detection technologies for biomarker discovery and clinical diagnostics. The company's NULISA platform enables researchers to detect and quantify thousands of proteins simultaneously, positioning it as a key player in the growing precision medicine market.
Key Facts
| Industry | Biotechnology |
| Founded | 2017 |
| Headquarters | Fremont, CA |
| Funding | Filed for IPO seeking to raise $150-159M through 9.375M shares priced at $15-$17 per share |
About Alamar Biosciences
Alamar Biosciences specializes in ultrasensitive protein detection and quantification technologies for life sciences research and clinical applications. The company's flagship NULISA platform combines the specificity of immunoassays with the sensitivity and scalability of next-generation sequencing to detect thousands of proteins simultaneously from small sample volumes.
The company serves pharmaceutical companies, academic researchers, and clinical laboratories seeking to identify and validate protein biomarkers for drug development and diagnostic applications. Alamar's technology addresses critical needs in precision medicine by enabling more comprehensive protein analysis than traditional methods, potentially accelerating biomarker discovery and therapeutic development timelines.
IPO Status
Alamar Biosciences has officially filed for an IPO, marking a significant milestone for the protein detection and biomarker company. The company has filed to offer 9.375 million shares priced between $15-$17 per share, aiming to raise approximately $150-159 million. The IPO filing comes with the ticker symbol ALMR and targets a valuation of around $1 billion. The filing represents the culmination of Alamar's growth in the proteomics market with its NULISA (Nucleic Acid-Linked Immuno-Sandwich Assay) technology platform. The company is now a revenue-generating business with its protein detection platform gaining traction among researchers and pharmaceutical companies. The IPO launch coincides with an improving biotech funding environment, as multiple life sciences companies are pursuing public offerings simultaneously.
Competitors
Frequently Asked Questions
Does Alamar Biosciences have a stock?
No, Alamar Biosciences has not had an IPO yet and remains a private company. The company is currently focused on commercializing its protein detection technology platform.
When is the Alamar Biosciences IPO date?
Alamar Biosciences has not announced a specific IPO date, though market speculation suggests potential public market activity. No confirmed details about timing have been disclosed by the company. Sign up for alerts to stay informed.
How can I buy Alamar Biosciences stock?
Since Alamar Biosciences is still private, you cannot buy shares on public exchanges. If the company goes public, shares would become available through standard brokerage platforms. Sign up for alerts to stay informed.
Stay Updated on the Alamar Biosciences IPO
Get real-time alerts when Alamar Biosciences files for an IPO, prices shares, or begins trading.
Get IPO Alerts